Jung J.H, et al. – The combination therapy with capecitabine and cisplatin for advanced biliary tract cancer (BTC) as a second–line regimen, was inspected. In some of the patients with advanced BTC, the recommended regimen could be an option for second–line chemotherapy.

Methods

• The medical records of 40 patients diagnosed with BTC who received palliative second-line chemotherapy with capecitabine and cisplatin, were reviewed.

Results

• As per the observations, the median overall survival from the start of second-line chemotherapy was 6.3 months.
• In addition, the median overall survival from diagnosis was 17.9 months.
• During second-line chemotherapy, the median progression-free survival was 2.3 months.
• Results revealed adverse events of grade ≥3 in nine (30%) patients.
• An independent predictor of adverse events was Eastern Cooperative Oncology Group performance score.